Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial

In much-needed good news for the radiopharmaceuticals group, Telix Pharmaceuticals (ASX:TLX) says the first stanza of its “highly innovative” phase III prostate cancer therapeutic trial has come up ...
The Manila Times

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Canc…

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Targeted Oncology

FDA OKs New Piflufolastat F 18 Formulation for Prostate Cancer Imaging

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...